Bristol-Myers Squibb Company (BMS)
Wallingford, CT and Princeton, NJ.

In 1995, Aphios entered into a three (3) year Collaborative Research Agreement with the Bristol-Myers Squibb Company (BMS) to screen a minimum of 10,000 marine microorganism extracts over a two (2) year period.  After screening 4,000 extracts. 120 “hits” were obtained in several different therapeutic areas: 63 anti-bacterial;14 anti-fungal; 14 cytotoxic; 9 immunology; 16 obesity; and 4 cardiovascular.  Six cytotoxic hits were against a murine lung cancer cell line in a screen for oncology.  These hits were obtained from two microorganisms which were isolated from a sponge with demonstrated bioactivity against a human lung cancer cell line.  Utilizing DNA fingerprinting and molecular taxonomy, one microbe was identified. BMS scaled-up both of these “hits” for chemical identification and dereplication.

Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer medicines, beauty care, nutritionals and medical devices.  BMS is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. BMS is also a leader in consumer medicines, orthopedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin care products.  Total company evenue exceeded $18 billion in 1998, with about 40 percent of sales outside the U.S. BMS' flagship medicines Pravachol (pravastatin sodium), TAXOL® (paclitaxel) and Glucophage (metformin) head the list of 64 product lines in key businesses that each have annual global sales of more than $50 million.  I n 1998, net earnings exceeded $3.6 billion, a 14 percent increase over 1997, and total return to shareholders reached 43 percent. Company wide research and development spending exceeded $1.5 billion in 1998.

For further informtaion on Bristol-Myers Squibb, visit www.bms.com.

Home l Company | Infectious Diseases | Oncology | Nutraceuticals | Product Pipeline | Purchase Products | Technology Platforms | Equipment |Patents | Press Releases | Contact Aphios